Advertisement
Advertisement
RPRX
Royalty Pharma plc Class A Ordinary Shares
58.41
USDSponsored
-0.52
-0.88%
Sep 18, 15:59 UTC -4
Closed
After-Market
58.70
+0.30
+0.51%
RPRX Earnings Reports
Positive Surprise Ratio
RPRX beat 14 of 25 last estimates.
56%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$860.20M
/$1.16
Implied change from Q2 26 (Revenue/ EPS)
+27.63%
/+16.00%
Implied change from Q3 25 (Revenue/ EPS)
+5.68%
/-0.85%
Royalty Pharma plc Class A Ordinary Shares earnings per share and revenue
On Aug 05, 2026, RPRX reported earnings of 1.00 USD per share (EPS) for Q2 26, missing the estimate of 1.30 USD, resulting in a -22.95% surprise. Revenue reached 674.00 million, compared to an expected 707.05 million, with a -4.67% difference. The market reacted with a +0.47% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 1.16 USD, with revenue projected to reach 860.20 million USD, implying an increase of 16.00% EPS, and increase of 27.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Royalty Pharma plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Royalty Pharma plc Class A Ordinary Shares reported EPS of $1.00, missing estimates by -22.95%, and revenue of $674.00M, -4.67% below expectations.
How did the market react to Royalty Pharma plc Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved up 0.47%, changed from $57.48 before the earnings release to $57.75 the day after.
When is Royalty Pharma plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Royalty Pharma plc Class A Ordinary Shares's next earnings report?
Based on 4
analysts, Royalty Pharma plc Class A Ordinary Shares is expected to report EPS of $1.16 and revenue of $860.20M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.